{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:11:58Z","timestamp":1790737918635,"version":"4.1.0"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:00:00Z","timestamp":1588982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/open-government-licence\/version\/2\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA12382"],"award-info":[{"award-number":["R01 DA12382"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21 DA020750"],"award-info":[{"award-number":["R21 DA020750"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21 DA030696"],"award-info":[{"award-number":["R21 DA030696"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21 DA031853-01"],"award-info":[{"award-number":["R21 DA031853-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH086769"],"award-info":[{"award-number":["MH086769"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R21 16311"],"award-info":[{"award-number":["R21 16311"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","award":["27340"],"award-info":[{"award-number":["27340"]}],"id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>There is increasing interest in the relationship between cannabinoids and psychosis. While individual human laboratory studies have been critical in demonstrating that cannabinoids (e.g., delta-9-tetrahydrocannabinol [THC]) can induce acute transient psychosis-like effects in healthy human volunteers, combining data from multiple studies offers a fine-grained view of these effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>THC-induced psychosis-relevant effects were examined using a data repository of 10 double-blind, randomized, placebo-controlled, crossover studies with 400 i.v. THC infusions in healthy human volunteers. The Positive and Negative Syndrome scale was used to measure psychotomimetic effects. The profile of symptoms, frequency of a response, its relationship to THC dose and substance use, latent structure in Positive and Negative Syndrome scale response, and the relationships between psychotomimetic and perceptual alteration symptoms were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Clinically meaningful increases in positive symptoms were noted in 44.75% infusions; conceptual disorganization, hallucinations, blunted affect, somatic concern, motor retardation, and poor attention were the items most frequently altered by THC. The increase in Positive and Negative Syndrome scale positive symptoms was positively associated with THC dose (beta\u2009=\u200911.13, SE\u2009=\u20094.94, Wald \u03c7\u200a2\u2009=\u200919.88, P\u2009&amp;lt;\u2009.001) and negatively associated with frequent cannabis use (beta\u2009=\u2009\u22120.575, SE\u2009=\u20090.14, Wald \u03c7\u200a2\u2009=\u200918.13, P\u2009&amp;lt;\u2009.001). Furthermore, positive symptoms were strongly correlated with Clinician Administered Dissociative States Scale perceptual alterations score (rs\u2009=\u20090.514, P\u2009&amp;lt;\u2009.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Intravenous administration of THC consistently induces psychotomimetic effects that include symptoms across Positive and Negative Syndrome scale domains. Moreover, healthy individuals who frequently use cannabis have a blunted psychotomimetic response.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijnp\/pyaa031","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T19:19:02Z","timestamp":1588706342000},"page":"559-570","source":"Crossref","is-referenced-by-count":42,"title":["Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1833-1986","authenticated-orcid":false,"given":"Suhas","family":"Ganesh","sequence":"first","affiliation":[{"name":"Schizophrenia Neuropharmacology Research Group, VA Connecticut Healthcare System, West Haven, CT"},{"name":"Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT"},{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Cortes-Briones","sequence":"additional","affiliation":[{"name":"Schizophrenia Neuropharmacology Research Group, VA Connecticut Healthcare System, West Haven, CT"},{"name":"Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT"},{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohini","family":"Ranganathan","sequence":"additional","affiliation":[{"name":"Schizophrenia Neuropharmacology Research Group, VA Connecticut Healthcare System, West Haven, CT"},{"name":"Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT"},{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Radhakrishnan","sequence":"additional","affiliation":[{"name":"Schizophrenia Neuropharmacology Research Group, VA Connecticut Healthcare System, West Haven, CT"},{"name":"Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT"},{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick D","family":"Skosnik","sequence":"additional","affiliation":[{"name":"Schizophrenia Neuropharmacology Research Group, VA Connecticut Healthcare System, West Haven, CT"},{"name":"Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT"},{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak Cyril","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"Schizophrenia Neuropharmacology Research Group, VA Connecticut Healthcare System, West Haven, CT"},{"name":"Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT"},{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,9]]},"reference":[{"key":"2020120619173136100_CIT0001","first-page":"134","article-title":"The structured clinical interview for DSM-IV axis I disorders (SCID-I) and the structured clinical interview for DSM-IV axis II disorders (SCID-II)","volume-title":"Personality assessment","author":"First","year":"2004"},{"key":"2020120619173136100_CIT0002","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.biopsych.2008.12.007","article-title":"Baseline and amphetamine-stimulated dopamine activity are related in drug-na\u00efve schizophrenic subjects","volume":"65","author":"Abi-Dargham","year":"2009","journal-title":"Biol Psychiatry"},{"key":"2020120619173136100_CIT0003","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-2007-979354","article-title":"The NMDA antagonist model for schizophrenia: promise and pitfalls","volume":"31 Suppl 2","author":"Abi-Saab","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"2020120619173136100_CIT0004","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1177\/0269881110382465","article-title":"Does intravenous Delta9-tetrahydrocannabinol increase dopamine release? A SPET study","volume":"25","author":"Barkus","year":"2011","journal-title":"J Psychopharmacol"},{"key":"2020120619173136100_CIT0005","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"2020120619173136100_CIT0006","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.biopsych.2013.05.027","article-title":"Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms","volume":"75","author":"Bloomfield","year":"2014","journal-title":"Biol Psychiatry"},{"key":"2020120619173136100_CIT0007","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nature20153","article-title":"The effects of \u03949-tetrahydrocannabinol on the dopamine system","volume":"539","author":"Bloomfield","year":"2016","journal-title":"Nature"},{"key":"2020120619173136100_CIT0008","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1177\/0269881118799953","article-title":"The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Delta(9)-THC) in humans","volume":"32","author":"Boggs","year":"2018","journal-title":"J Psychopharmacol"},{"key":"2020120619173136100_CIT0009","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/npp.2008.138","article-title":"Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum","volume":"34","author":"Bossong","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"2020120619173136100_CIT0010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J Trauma Stress"},{"key":"2020120619173136100_CIT0011","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.biopsych.2015.12.002","article-title":"Acute and chronic effects of cannabinoids on human cognition-a systematic review","volume":"79","author":"Broyd","year":"2016","journal-title":"Biol Psychiatry"},{"key":"2020120619173136100_CIT0012","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00213-011-2417-y","article-title":"The safety of studies with intravenous \u0394\u200a9-tetrahydrocannabinol in humans, with case histories","volume":"219","author":"Carbuto","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"2020120619173136100_CIT0013","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/adb.12116","article-title":"[18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users","volume":"20","author":"Ceccarini","year":"2015","journal-title":"Addict Biol"},{"key":"2020120619173136100_CIT0014","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s40473-017-0120-y","article-title":"Molecular basis of cannabis-induced schizophrenia-relevant behaviours: insights from animal models","volume":"4","author":"Chesworth","year":"2017","journal-title":"Current Behavioral Neuroscience Reports"},{"key":"2020120619173136100_CIT0015","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.biopsych.2015.03.023","article-title":"The psychosis-like effects of \u0394(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans","volume":"78","author":"Cortes-Briones","year":"2015","journal-title":"Biol Psychiatry"},{"key":"2020120619173136100_CIT0016","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","article-title":"The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis","volume":"29","author":"D\u2019Souza","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"2020120619173136100_CIT0017","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.npp.1301643","article-title":"Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis","volume":"33","author":"D\u2019Souza","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"2020120619173136100_CIT0018","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00213-007-1042-2","article-title":"Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans","volume":"198","author":"D\u2019Souza","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"2020120619173136100_CIT0019","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00406-009-0024-2","article-title":"Cannabis and psychosis\/schizophrenia: human studies","volume":"259","author":"D\u2019Souza","year":"2009","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2020120619173136100_CIT0020","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/npp.2012.8","article-title":"Dose-related modulation of event-related potentials to novel and target stimuli by intravenous \u0394\u200a9-THC in humans","volume":"37","author":"D\u2019Souza","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"2020120619173136100_CIT0021","first-page":"60","article-title":"Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis","volume":"1","author":"D\u2019Souza","year":"2016","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"2020120619173136100_CIT0022","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S2215-0366(18)30427-9","article-title":"Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial","volume":"6","author":"D\u2019Souza","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"2020120619173136100_CIT0023","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2215-0366(19)30048-3","article-title":"The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study","volume":"6","author":"Di Forti","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"2020120619173136100_CIT0024","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1749-6632.1971.tb13996.x","article-title":"Neuropsychopharmacologic studies of marijuana: some synthetic and natural thc derivatives in animals and man","volume":"191","author":"Domino","year":"1971","journal-title":"Annals of the New York Academy of Sciences"},{"key":"2020120619173136100_CIT0025","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.neuroscience.2010.06.011","article-title":"Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex","volume":"169","author":"Eggan","year":"2010","journal-title":"Neuroscience"},{"key":"2020120619173136100_CIT0026","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/0091-3057(91)90383-D","article-title":"Reduced binocular depth inversion as an indicator of cannabis-induced censorship impairment","volume":"40","author":"Emrich","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"2020120619173136100_CIT0027","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0091-3057(96)00426-1","article-title":"Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system","volume":"56","author":"Emrich","year":"1997","journal-title":"Pharmacol Biochem Behav"},{"key":"2020120619173136100_CIT0028","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.2174\/138161212802884618","article-title":"Cannabis in the arm: what can we learn from intravenous cannabinoid studies?","volume":"18","author":"Englund","year":"2012","journal-title":"Curr Pharm Des"},{"key":"2020120619173136100_CIT0029","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/ejn.13951","article-title":"Delta-9-tetrahydrocannabinol potentiates fear memory salience through functional modulation of mesolimbic dopaminergic activity states","volume":"47","author":"Fitoussi","year":"2018","journal-title":"Eur J Neurosci"},{"key":"2020120619173136100_CIT0030","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1176\/appi.ajp.2010.09020189","article-title":"Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization","volume":"167","author":"Foti","year":"2010","journal-title":"Am J Psychiatry"},{"key":"2020120619173136100_CIT0031","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","article-title":"Serotonin research: contributions to understanding psychoses","volume":"29","author":"Geyer","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"2020120619173136100_CIT0032","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/mp.2011.82","article-title":"Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers","volume":"17","author":"Hirvonen","year":"2012","journal-title":"Mol Psychiatry"},{"key":"2020120619173136100_CIT0033","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.addbeh.2011.11.025","article-title":"Validity of timeline follow-back for self-reported use of cannabis and other illicit substances\u2014systematic review and meta-analysis","volume":"37","author":"Hjorth\u00f8j","year":"2012","journal-title":"Addic Behav"},{"key":"2020120619173136100_CIT0034","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1360-0443.2011.03757.x","article-title":"Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial","volume":"107","author":"Hjorth\u00f8j","year":"2012","journal-title":"Addiction"},{"key":"2020120619173136100_CIT0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cpt1973143353","article-title":"Delta-8- and delta-9-tetrahydrocannabinol; comparison in man by oral and intravenous administration","volume":"14","author":"Hollister","year":"1973","journal-title":"Clin Pharmacol Ther"},{"key":"2020120619173136100_CIT0036","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF00690920","article-title":"Increased susceptibility to memory intrusions and the Stroop interference effect during acute marijuana intoxication","volume":"91","author":"Hooker","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"2020120619173136100_CIT0037","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"2020120619173136100_CIT0038","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0447.2005.00741.x","article-title":"Validity and reliability of the CAPE: a self-report instrument for the measurement of psychotic experiences in the general population","volume":"114","author":"Konings","year":"2006","journal-title":"Acta Psychiatr Scand"},{"key":"2020120619173136100_CIT0039","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archpsyc.62.9.985","article-title":"Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function","volume":"62","author":"Krystal","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"2020120619173136100_CIT0040","first-page":"1182","article-title":"SPECT imaging of striatal dopamine release after amphetamine challenge","volume":"36","author":"Laruelle","year":"1995","journal-title":"J Nucl Med"},{"key":"2020120619173136100_CIT0041","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/jat\/bkv082","article-title":"Plasma cannabinoid pharmacokinetics after controlled smoking and ad libitum cannabis smoking in chronic frequent users","volume":"39","author":"Lee","year":"2015","journal-title":"J Anal Toxicol"},{"key":"2020120619173136100_CIT0042","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000026487","article-title":"The effects of tetrahydrocannabinol on the recognition of emotionally charged words: an analysis using event-related brain potentials","volume":"37","author":"Leweke","year":"1998","journal-title":"Neuropsychobiology"},{"key":"2020120619173136100_CIT0043","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130050884","article-title":"Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man","volume":"142","author":"Leweke","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"2020120619173136100_CIT0044","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0091-3057(00)00201-X","article-title":"Different effects of nabilone and cannabidiol on binocular depth inversion in man","volume":"66","author":"Leweke","year":"2000","journal-title":"Pharmacol Biochem Behav"},{"key":"2020120619173136100_CIT0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.schres.2013.03.019","article-title":"A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities","volume":"147","author":"Lindenmayer","year":"2013","journal-title":"Schizophr Res"},{"key":"2020120619173136100_CIT0046","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2008.02.020","article-title":"The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis","volume":"103","author":"Mason","year":"2008","journal-title":"Schizophr Res"},{"key":"2020120619173136100_CIT0047","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0006-8993(98)00375-8","article-title":"Cerebellar activity and disturbed time sense after THC","volume":"797","author":"Mathew","year":"1998","journal-title":"Brain Res"},{"key":"2020120619173136100_CIT0048","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/archpsyc.1974.01760120099014","article-title":"Temporal disorganization and delusional-like ideation. Processes induced by hashish and alcohol","volume":"30","author":"Melges","year":"1974","journal-title":"Arch Gen Psychiatry"},{"key":"2020120619173136100_CIT0049","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajmg.b.32177","article-title":"What can we learn about schizophrenia from studying the human model, drug-induced psychosis?","volume":"162B","author":"Murray","year":"2013","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"2020120619173136100_CIT0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1034\/j.1600-0447.2002.1o079.x","article-title":"Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia","volume":"105","author":"N\u00fa\u00f1ez","year":"2002","journal-title":"Acta Psychiatr Scand"},{"key":"2020120619173136100_CIT0051","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"2020120619173136100_CIT0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnbeh.2011.00001","article-title":"Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light","volume":"5","author":"Paparelli","year":"2011","journal-title":"Front Behav Neurosci"},{"key":"2020120619173136100_CIT0053","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41593-018-0206-1","article-title":"GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia","volume":"21","author":"Pasman","year":"2018","journal-title":"Nat Neurosci"},{"key":"2020120619173136100_CIT0054","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00213-009-1514-7","article-title":"The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms?","volume":"206","author":"Peleg-Raibstein","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"2020120619173136100_CIT0055","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/npp.2015.58","article-title":"GABA deficits enhance the psychotomimetic effects of \u03949-THC","volume":"40","author":"Radhakrishnan","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"2020120619173136100_CIT0056","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.biopsych.2012.06.012","article-title":"Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the \u03ba opioid agonist Salvinorin A in humans","volume":"72","author":"Ranganathan","year":"2012","journal-title":"Biol Psychiatry"},{"key":"2020120619173136100_CIT0057","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1017\/S1461145711001830","article-title":"Naltrexone does not attenuate the effects of intravenous \u03949-tetrahydrocannabinol in healthy humans","volume":"15","author":"Ranganathan","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"2020120619173136100_CIT0058","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1007\/s00213-019-05273-5","article-title":"Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans","volume":"236","author":"Ranganathan","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"2020120619173136100_CIT0059","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.biopsych.2016.01.011","article-title":"Human laboratory studies on cannabinoids and psychosis","volume":"79","author":"Sherif","year":"2016","journal-title":"Biol Psychiatry"},{"key":"2020120619173136100_CIT0060","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.biopsych.2015.12.011","article-title":"It\u2019s all in the rhythm: the role of cannabinoids in neural oscillations and psychosis","volume":"79","author":"Skosnik","year":"2016","journal-title":"Biol Psychiatry"},{"key":"2020120619173136100_CIT0061","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","article-title":"Timeline follow-back: a technique for assessing selfreported alcohol consumption","volume-title":"Measuring Alcohol Consumption: Psychosocial and Biological Methods","author":"Sobell","year":"1992"},{"key":"2020120619173136100_CIT0062","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1176\/appi.ajp.2017.17020223","article-title":"Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis","volume":"175","author":"Starzer","year":"2018","journal-title":"Am J Psychiatry"},{"key":"2020120619173136100_CIT0063","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/2045125314557797","article-title":"Drug models of schizophrenia","volume":"5","author":"Steeds","year":"2015","journal-title":"Ther Adv Psychopharmacol"},{"key":"2020120619173136100_CIT0064","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.neuroimage.2009.06.029","article-title":"Can recreational doses of THC produce significant dopamine release in the human striatum?","volume":"48","author":"Stokes","year":"2009","journal-title":"Neuroimage"},{"key":"2020120619173136100_CIT0065","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-3-319-90365-1_14","article-title":"The association between cannabinoids and psychosis","volume-title":"Cannabis Use Disorders","author":"Tikka","year":"2019","edition":"eds"},{"key":"2020120619173136100_CIT0066","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.schres.2006.03.021","article-title":"The five-factor model of the positive and negative syndrome scale II: a ten-fold cross-validation of a revised model","volume":"85","author":"van der Gaag","year":"2006","journal-title":"Schizophr Res"},{"key":"2020120619173136100_CIT0067","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/mp.2016.252","article-title":"Cannabis use and risk of schizophrenia: a Mendelian randomization study","volume":"23","author":"Vaucher","year":"2018","journal-title":"Mol Psychiatry"},{"key":"2020120619173136100_CIT0068","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2012.01.031","article-title":"Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia","volume":"137","author":"Wallwork","year":"2012","journal-title":"Schizophr Res"},{"key":"2020120619173136100_CIT0069","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0896-6273(01)00372-5","article-title":"Presynaptic specificity of endocannabinoid signaling in the hippocampus","volume":"31","author":"Wilson","year":"2001","journal-title":"Neuron"},{"key":"2020120619173136100_CIT0070","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/35069076","article-title":"Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses","volume":"410","author":"Wilson","year":"2001","journal-title":"Nature"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaa031\/33405706\/pyaa031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/23\/9\/559\/34673077\/pyaa031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/23\/9\/559\/34673077\/pyaa031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T02:24:25Z","timestamp":1607307865000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/23\/9\/559\/5834890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,9]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaa031","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,1]]},"published":{"date-parts":[[2020,5,9]]}}}